Abeona Therapeutics

ABEOPhase 3

Cleveland, United Statesabeonatherapeutics.com

Abeona Therapeutics is dedicated to delivering transformative cell and gene therapies for patients with severe rare diseases. The company has achieved a significant milestone with the commercial launch of ZEVASKYN® and maintains a diverse pipeline spanning preclinical to Phase 1/2 development, primarily targeting inherited retinal diseases and neurological conditions. Its strategy is supported by in-house manufacturing capabilities at The Elisa Linton Center for Rare Disease Therapies and key partnerships with Ultragenyx and Taysha Gene Therapies.

Focus

BiologicsRNA & Gene Therapy

ABEO · Stock Price

USD 5625.0021250.00 (-79.07%)

Historical price data

AI Company Overview

Technology Platform

Proprietary AIM™ (Abeona Integration Machine) vector platform based on adeno-associated virus (AAV) technology, designed for enhanced gene delivery and transduction efficiency in target tissues.

Pipeline Snapshot

9 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
ofloxacin + MSI-78	Diabetic Foot Ulcers	Phase 3
ofloxacin + MSI-78	Diabetic Foot Ulcers	Phase 3
EB-101	Epidermolysis Bullosa	Phase 3
EB-101 Surgical application of RDEB wounds	Epidermolysis Bullosa	Phase 3
EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)	Onychomycosis	Phase 2

Opportunities

Significant growth opportunities exist in expanding the commercial footprint of ZEVASKYN® and advancing the promising preclinical retinal disease pipeline (ABO-503, ABO-504, ABO-505) into clinical trials.

Successful data readouts from partnered programs with Ultragenyx and Taysha could also unlock substantial value through milestone payments and royalties.

Risk Factors

Key risks include the commercial execution challenge for ZEVASKYN®, the high failure rate inherent in drug development for the preclinical/clinical pipeline, potential future dilution from capital raises, and intense competition in the gene therapy space from larger, better-funded rivals.

Competitive Landscape

Abeona faces competition across its therapeutic areas, including from established gene therapy leaders like Spark/Roche in retinal diseases and various biotechs in neurological disorders. Its differentiation is based on the proprietary AIM™ vector platform and integrated in-house manufacturing, but it must demonstrate clinical superiority and execute effectively in a crowded market.